Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
In the present report, investigations have been carried out to evaluate toxic and therapeutic effects of cyclophosphamide vs its isomer iphosphamide. Cytostatic action of the 2 drugs was assayed on the murine Lewis lung carcinoma (3LL). It has been observed that iphosphamide is less toxic as compared to cyclophosphamide (LD50 IP LD50 CP = 1.5); on the other hand, to reach the same therapeutic effectiveness on 3LL, an iphosphamide dose 1.6 - 2 times higher than that of its parent compound is necessary.
D000818:Animals; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000627:therapeutic use* / Q000633:toxicity; D007069:Ifosfamide / Q000627:therapeutic use* / Q000633:toxicity; D007928:Lethal Dose 50; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy
D003520:Cyclophosphamide; D007069:Ifosfamide